CJC-1295 vs Sermorelin: Which GHRH Analog Should You Choose?

CJC-1295 vs Sermorelin: Side-by-Side

Why Two Peptides for the Same Receptor?

Sermorelin is the shorter, more established molecule — a truncated fragment of natural GHRH with decades of clinical use behind its original pediatric indication. Its short half-life closely mimics the body's own GHRH pulse, which is part of why some clinicians prefer it for a more "physiological" pattern of GH release.

CJC-1295 was developed to solve sermorelin's biggest practical drawback: it breaks down too fast to matter much beyond the injection window. The DAC (Drug Affinity Complex) modification binds CJC-1295 to albumin in the blood, extending its half-life from minutes to days. The trade-off is that DAC-modified CJC-1295 produces a flatter, more continuous GH elevation rather than the sharp nighttime pulse associated with natural release — which is why many protocols use the no-DAC version, dosed daily, to preserve pulsatility while still gaining a modest duration advantage over sermorelin.

When to Choose Sermorelin

Sermorelin fits people who want the more studied, longer clinical track record of the two compounds, or who are working with a provider who prefers dosing that mirrors natural GHRH pulses as closely as possible. Its short half-life also means it clears the body quickly, which some users prefer from a control standpoint — there's no lingering effect if you want to stop.

When to Choose CJC-1295

CJC-1295 (no-DAC) is generally preferred by protocols aiming to match ipamorelin's once- or twice-daily schedule without adding a second molecule with a very different half-life. CJC-1295 with DAC appeals to people prioritizing dosing convenience (1-2 injections a week) over the sharper pulse pattern of the shorter-acting options. Neither version is FDA-approved, so sourcing quality and physician supervision matter more here than with sermorelin.

Should You Combine CJC-1295 and Sermorelin?

Stacking CJC-1295 and sermorelin together is generally not useful, because both act on the same GHRH receptor — combining them is redundant rather than synergistic, unlike pairing a GHRH analog with a GHRP (ghrelin-receptor agonist) such as ipamorelin, which activates a different receptor and does produce an additive GH pulse. Most protocols pick one GHRH analog (sermorelin or CJC-1295) and pair it with a GHRP, rather than combining two GHRH analogs. See our CJC-1295 + ipamorelin stack guide for how that pairing works in practice.